StreetInsider.com News Articles

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncology (ESMO) meeting, taking place on October 23-27 in Madrid, Spain. The presentations will feature data updates from across IDEAYA's clinical pipeline, including multiple ongoing trials of darovasertib in uveal melanoma, including the registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial in HLA*A2:01-positive mUM, and the Phase 2 OptimUM-09 trial

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

Fri, 17 Jul 2026 09:00:00 -0400

Form 4 IDEAYA Biosciences, Inc. For: Jul 07 Filed by: Ruiz Briseno Andres

Thu, 09 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260709/26753809.html

Form 4 IDEAYA Biosciences, Inc. For: Jul 07 Filed by: Ruiz Briseno Andres

Thu, 09 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260709/26753809.html

Form 144 IDEAYA Biosciences, Inc. Filed by: Ruiz Briseno Andres

Tue, 07 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260707/26742476.html

Form 144 IDEAYA Biosciences, Inc. Filed by: Ruiz Briseno Andres

Tue, 07 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260707/26742476.html

Ideaya Biosciences (IDYA) PT Lowered to $48 at RBC Capital

Tue, 07 Jul 2026 08:00:08 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $53.00) while maintaining a Outperform rating.

Ideaya Biosciences (IDYA) PT Lowered to $63 at Truist Securities

Tue, 07 Jul 2026 07:09:15 -0400

Truist Securities analyst Greg Renza lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $63.00 (from $65.00) while maintaining a Buy rating.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 26 Jun 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 25, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 98,000 shares of the Company's common stock to four newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 26 Jun 2026 06:00:00 -0400

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 26 Jun 2026 06:00:00 -0400

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 26 Jun 2026 06:00:00 -0400

Form 8-K IDEAYA Biosciences, Inc. For: Jun 16

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679469.html

Form 8-K IDEAYA Biosciences, Inc. For: Jun 16

Tue, 23 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260623/26679469.html

Form 4 IDEAYA Biosciences, Inc. For: Jun 16 Filed by: Stein Jeffrey

Thu, 18 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260618/26666673.html